| 56.99 0.02 (0.04%) | 08-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Morphic Holding, Inc. is a biopharmaceutical company dedicated to the discovery and advancement of oral, small-molecule integrin-based therapies. These treatments are designed to address a broad spectrum of conditions, including autoimmune, cardiovascular, and metabolic diseases, as well as various forms of fibrosis and cancer. The company's principal therapeutic candidates include MORF-057, an a4ß7-specific integrin inhibitor targeting inflammation, currently undergoing Phase 1 clinical trials for inflammatory bowel disease and in preclinical development for idiopathic pulmonary fibrosis and other fibrotic ailments. Additionally, Morphic is progressing avß6 for fibrotic disorders and avß8 for solid tumor applications, alongside a pipeline of other innovative products. Morphic has established strategic collaborations, including a research partnership with Engitix Ltd concerning integrin technology for fibrostenotic IBD, an agreement with Schrödinger, LLC focused on integrin targets, and a licensing arrangement with Children's Medical Center Corporation for the global development and commercialization of products for human and veterinary therapeutic or diagnostic uses. Further collaborative efforts involve AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. for the discovery and development of integrin-based therapeutics. Established in 2014, Morphic Holding, Inc. operates from its headquarters in Waltham, Massachusetts.
Tue, 27 Aug 2024
Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline - BioPharm International
Fri, 16 Aug 2024
Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease - PR Newswire
Mon, 12 Aug 2024
Eli Lilly Taps Blue-Chip Bond Market to Fund Morphic Acquisition - Bloomberg.com
Mon, 08 Jul 2024
Dow Turns Lower; Myomo Shares Jump - Quantisnow
Mon, 08 Jul 2024
Eli Lilly buys Waltham biotech for $3.2B - The Business Journals
Mon, 08 Jul 2024
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|